Compare
Branded vs compounded GLP-1s, explained
Cost, legality, and oversight differ between brand-name GLP-1s and their compounded counterparts. Here's a structured way to think about the trade-offs.
12 min read · Updated 2026-05-22
Peptide GPS publishes educational information, not medical advice. We don't sell, prescribe, or recommend specific medications, dosages, or providers. Always discuss any therapy with a licensed clinician.
The two main categories
Branded GLP-1s are FDA-approved drugs manufactured by their original sponsors (e.g. Novo Nordisk, Eli Lilly) and dispensed through licensed pharmacies. Examples include Ozempic and Wegovy (semaglutide), and Mounjaro and Zepbound (tirzepatide).
Compounded GLP-1s are versions prepared by compounding pharmacies — either 503A pharmacies serving individual prescriptions or 503B outsourcing facilities producing larger batches under stricter FDA oversight.
The molecule on the label can be the same word in both cases. That sameness is doing a lot of work in marketing copy, and not as much work as you'd think in the underlying product.
Why compounded versions exist
Compounding has historically expanded when an FDA-approved drug appears on the FDA shortage list, which temporarily permits compounders to prepare 'essentially copies' under specific conditions.
As GLP-1 supply has stabilized, the FDA has been clarifying its policy for compounders, and enforcement around marketing has increased. This is an actively shifting regulatory area — what was permissible last quarter may not be permissible next quarter.
The practical consequence: a clinic offering compounded GLP-1s today may need to change its offering on short notice. That's not necessarily a red flag — it's the nature of the lane — but it is a reason to ask the clinic what their contingency plan is, in writing.
What actually differs
Price, oversight, and consistency are the main practical differences. Branded products carry standardized manufacturing, dosing devices, and labeling. Compounded products vary in formulation, fill volumes, additives, and quality controls between pharmacies.
Insurance coverage, prior authorization requirements, and lab-monitoring expectations also differ. None of this tells you which is 'right' — only that they are not interchangeable from a clinical, financial, or legal standpoint.
Two specific differences worth understanding. First, dose units: a branded pen delivers a known dose per click; a compounded vial dispensed for self-draw asks you to measure, and small measurement errors compound week over week. Second, additives: some compounded formulations include B12 or other adjuncts that change side-effect profiles and complicate troubleshooting if you feel off.
Cost, honestly
Cash-pay pricing on branded GLP-1s has been falling as direct-to-patient programs from the manufacturers expand, but is still often higher than compounded. Insurance coverage for the weight-loss indications (Wegovy, Zepbound) is uneven; coverage for the diabetes indications (Ozempic, Mounjaro) is broader but tied to a diagnosis you may or may not have.
Compounded is usually — but not always — cheaper. The cheapest cash price you see online is rarely the price you end up paying once labs, follow-ups, and dose escalations are included. Compare total 12-month cost, not introductory month.
Questions that separate good clinics from bad ones
If compounded: which pharmacy, 503A or 503B, what's in the vial besides the active ingredient, and what's your plan when the relevant FDA shortage listing ends?
If branded: are you helping me work through prior authorization, or am I on my own with the insurer?
For either: who is the prescribing clinician, what's their license, and how do I reach them between appointments?
Key takeaways
- Branded and compounded GLP-1s are legally and clinically distinct.
- Compounding rules tighten when shortages end — check current FDA status.
- Compare oversight and consistency, not just price.
- Total 12-month cost matters more than the introductory month.
- Ask the clinic, in writing, what happens when FDA shortage listings change.
Get the weekly brief
One plain-English email per week on GLP-1s, peptides, and the regulation around them.